TAG:
clinical trials
Developing Technology Expected To Fuel Boom In Anatomic Pathology
CEO SUMMARY: Established demographic trends point to a coming boom in the demand for anatomic pathology services. Greater number s of senior citizens, living longer lives, will raise the number of cancer cases diagnosed annually in the United States. New diagnostic technology will increas…
AutoCyte to Buy NSI’s Patents and Other Assets
CEO SUMMARY: When Neuromedical Systems entered Chapter 11 bankruptcy, AutoCyte moved rapidly to purchase Neuromedical’s patents and other intellectual property for automated cytology technology. Even as Neuromedical disappears from the marketplace, AutoCyte is preparing its entry. Labor…
Movers & Shakers For ’99 Demonstrate Leadership
EACH YEAR IT BECOMES more difficult to make final selections for our annual Movers & Shakers awards. The reason is simple. Today there are more examples of leadership in the laboratory than when we first started these selections three years ago. This is a good omen. It means that the crucible of…
Quest to Pay $1.27 Billion To Buy SB’s Lab Division
CEO SUMMARY: Consolidation is the story of the clinical laboratory industry during the 1990s. The decade will close out with the granddaddy laboratory consolidation of them all! When Quest Diagnostics Incorporated completes its acquisition of SmithKline Beecham Clinical Laboratories later…
PPM Giant MedPartners Exits Doctor Management
THIRD IN A SERIES WHAT DOES IT MEAN WHEN the largest companies in a multibillion dollar industry announce that they will “get out” of that business? That is the question which must be answered after MedPartners, Inc. joined PhyMatrix Corp. in p…
Chiron Is Biotech Firm, Respected For Innovation
CEO SUMMARY: Chiron is respected for its leadership in branched DNA and viral load technologies. The company had high expectations for its diagnostics group, particularly after its purchase of Ciba Corning. But rapid consolidation of the diagnostics industry changed Chiron’s opportunity…
AutoCyte Moves One Step Closer To FDA Approval
CEO SUMMARY: Until now, AutoCyte has kept a relatively quiet presence in the automated cytology marketplace. That may soon change as the FDA takes action on the company’s PREP™ and SCREEN™ products. AutoCyte expects these products will boost productivity and quality in cytology labs…
Pharmacogenomics Is The Coming Wave
CEO SUMMARY: It may be gloom and doom today in the clinical laboratory industry, but long term prospects for diagnostic testing are brightening. Increased understanding of human genetics drives new discoveries about how and why the same drug affects individuals differently. Biotech compan…
AccuMed, AutoCyte, Cytyc, MorphoMetrix, Neuromedical, NeoPath
Automated Cytology Update As predicted by THE DARK REPORT, the field of automated cytology has become a boiling pot, filled with controversy and change. Profits are meager. As we expected, the major issue revolves around the cost of this enhanced technology versus the measurable…
Rate of Change Follows a Geometric Curve
JANUARY WAS A WILD MONTH FOR COMPANIES OFFERING automated cytology products. January opened with new CPT codes for automated cytology procedures taking effect. January closed with news that the FDA’s advisory panel, convened on January 28, recommended approval of the PMA supplement of NeoPath, Inc…
CURRENT ISSUE
Volume XXXII, No. 6 – April 21, 2025
Now that a federal judge has vacated the FDA’s LDT rule, The Dark Report analyzes the judgement and notes the various steps the FDA could take in response. Also, lab testing at pharmacies is proving to be less successful than was once anticipated.
See the full table of contentsHow Much Laboratory Business Intelligence Have You Missed?
Lab leaders rely on THE DARK REPORT for actionable intelligence on important developments in the business of laboratory testing. Maximize the money you make-and the money you keep! Best of all, it is released every three weeks!
Sign up for TDR Insider
Join the Dark Intelligence Group FREE and get TDR Insider FREE!
Never miss a single update on the issues that matter to you and your business.